97217 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
Sub-classes:IMMUNOGLOBULIN VARIABLE DOMAINS
#2Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof
#3METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#4ENHANCED PROTEIN COMPOSITIONS
#5METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#6METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#7IGM ANTIBODIES DEGRADING IGG
#8IL10 AGONISTS AND METHODS OF USE THEREOF
#9METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS
#10SCAFFOLD PROTEINS
#11COMPOSITIONS AND METHODS FOR IDENTIFYING SUBJECTS WHO MAY BENEFIT FROM TREATMENT WITH THERAPEUTIC AGENTS
#12RABBIT ANTIBODIES TO HUMAN IMMUNOGLOBULINS G
#13MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF
#14RECOMBINANT IMMUNE COMPLEXES TARGETING HERPES SIMPLEX VIRUS
#15Library of Antigen-Binding Molecules Including Modified Antibody Variable Region
#16MODIFIED PROTEINS AND PEPTIDES
#17SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF
#18METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#19Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
#20MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE
#21ANTIBODY BINDING TO LINKER OF scFv OR LIKE
#22CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
#23DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF
#24Scaffold proteins
#25T CELL REGULATION
#26POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR
#27COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
#28MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF
#29ANTI-IgG NANOBODIES
#30BIOTIN DERIVATIVES
#31SYSTEMS AND REAGENTS FOR DETECTION OF FREE MONOCLONAL IMMUNOGLOBULIN LIGHT CHAINS IN BIOLOGICAL SAMPLES
#32Materials and methods for enhanced linker targeting
#33ANTI-CEA ANTIBODIES
#34ANTIGEN BINDING RECEPTORS
#35METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE
#36IL10 agonists and methods of use thereof
#37MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISITING INTERACTIONS
#38METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#39INJECTABLE HIGH-DRUG-LOADED NANOCOMPOSITE GELS AND PROCESS FOR MAKING THE SAME
#40Methods of permeabilizing the blood brain barrier
#41BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION
#42IgG EPITOPE PEPTIDES THAT BIND RHEUMATOID FACTOR AND METHODS OF USE THEREOF
#43CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
#44COMBINATION OF TWO OR MORE ANTI-C5 ANTIBODIES AND METHODS OF USE
#45REAGENTS AND METHODS FOR ANTIBODY SEQUENCING
#46HUMAN GENOME-DERIVED POLYNUCLEOTIDE AND METHOD FOR PRODUCING POLYPEPTIDE OF INTEREST USING SAME
#47ANTI-LAMBDA MYELOMA ANTRIGEN (LMA) BINDING PROTEINS TO TREAT LMA-EXPRESSING CANCER AND AUTOIMMUNE DISORDERS
#48CALIBRATION AND QUALITY CONTROL REAGENTS FOR USE WITH IMMUNOASSAYS FOR ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
#49ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE
#50ASSAY FOR PLASMA CELL ASSOCIATED DISEASE
#51SWITCHING BINDER, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION, ASSAY KIT, AND ANTIGEN AND ANTIBODY ASSAY METHOD, EACH USING SAME
#52SOURCE SPECIFIC EXOSOMES FOR DETERMINING AVOIDANCE OF CANCER TREATMENT AND AVOIDANCE OF CHECKPOINT INHIBITOR THERAPIES
#53MONOCLONAL ANTIBODY FOR DETECTION OF CAR-T CELLS, KIT AND APPLICATION
#54ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY
#55Compositions and Methods to Expedite Antibody-Based Exchange Imaging
#56IMMUNOGLOBULIN VARIABLE DOMAINS
#57IMMUNOGLOBULIN VARIABLE DOMAINS
#58Anti-VHH Domain Antibodies and Use Thereof
#59Antibody binding to a linker peptide
#60Immunoglobulin variable domains
#61METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS
#62Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
#63TWO CHIMERIC ANTIGEN RECEPTORS SPECIFICALLY BINDING CD19 AND IGKAPPA
#64Immunoglobulin variable domains
#65Separating agent
#66Immunoglobulin variable domains
#67TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#68Activatable anti-VEGF scFv
#69COMPOSITIONS AND METHODS FOR DETECTING AND TREATING TYPE 1 DIABETES AND OTHER AUTOIMMUNE DISEASES
#70Library of antigen-binding molecules including modified antibody variable region
#71ANTI-CEA ANTIBODIES
#72IL10 agonists and methods of use thereof
#73METHOD FOR AFFINITY PURIFICATION
#74DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF
#75METHODS OF TREATING COVID-19 MEDIATED LUNG DAMAGE USING SURFACTANTS AND NATURAL ANTIBODIES
#76ENHANCED PRODUCTION OF IMMUNOGLOBULINS
#77Immunoglobulin variable domains
#78Immunoglobulin variable domains
#79Immunoglobulin variable domains
#80COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#81Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders
#82T CELL REGULATION
#83METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#84COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE
#85METHOD FOR DECREASING IMMUNOGENICITY
#86Anti-variant Fc-region antibodies and method of use
#87USE OF TRYPTOPHAN DERIVATIVES AND L-METHIONINE FOR PROTEIN FORMULATION
#88Monoclonal antibody against nerve growth factor, and encoding gene and use thereof
#89Anti-human IgG4 monoclonal antibody and methods of making and using same
#90Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease
#91Immunoglobulin variable domains
#92Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
#93MODIFIED PROTEINS AND PEPTIDES
#94Recombinant Cell Surface Capture Proteins
#95Method for generating multispecific antibodies from monospecific antibodies
#96ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY
#97COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
#98Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#99BIOMARKERS FOR PREDICTING PROGNOSIS OF KIDNEY DISEASE
#100Kit for detecting coronary artery disease comprising an MAA protein adduct and reagents that bind to antibodies
#101METHOD
#102Immunoglobulin variable domains
#103Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#104IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS
#105Scaffold proteins
#106Asymmetric multispecific antibodies
#107Anti-IgM/B cell surface antigen bispecific antibody
#108ASSAY FOR PLASMA CELL ASSOCIATED DISEASE
#109Method of Selecting for Antibodies
#110TARGET DETECTION USING A MONOVALENT ANTIBODY
#111COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS
#112Modifying binding molecules to minimize pre-exisiting interactions
#113Biotin derivatives
#114Compositions and Methods for Identifying Subjects Who May Benefit From Treatment With Therapeutic Agents
#115Humanized anti-BASIGIN antibodies and the use thereof
#116Dual receptor antagonistic antigen-binding proteins and uses thereof
#117Use of a polymeric mesh for the purification of macromolecules
#118IMMUNODIAGNOSTIC DETECTION OF ANTI-NEUTROPHIL ANTIBODIES
#119Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties
#120Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure
#121ANTI-CEA ANTIBODIES
#122IDENTIFICATION AND PRODUCTION OF HIGH AFFINITY IGM ANTIBODIES AND DERIVATIVES THEREOF
#123METHOD FOR DETERMINING MORBIDITY TO DIABETES
#124MASS SPECTROMETRY KIT
#125Clinical assessment of M-protein response in multiple myeloma
#126METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE-RELATED DISEASES OR DISORDERS AND/OR THERAPY MONITORING
#127Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating HIV infection
#128Methods for Early Diagnosis of Kidney Disease
#129Compositions and methods to expedite antibody-based exchange imaging
#130TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#131Anti-variant Fc-region antibodies and method of use
#132Separating agent for human serum-derived IgG polyclonal antibodies, and method for separating human serum-derived IgG polyclonal antibodies using same
#133Circulating antibodies against MAA adducts as biomarker for coronary artery disease
#134Antigen-Binding Protein Directed Against Epitope in the CH1 Domain of Human IgG Antibodies
#135Chip for detecting allergy, manufacturing method thereof and a method for detecting allergy using therefor
#136Library of antigen-binding molecules including modified antibody variable region
#137ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY
#138Anti-surrogate light chain antibodies
#139Combined Tissue Resonance Suppression Therapy and Autologous Polyvalent Biological Vaccine
#140Methods of increasing T cell immune response in the treatment of cancer
#141Bispecific binding proteins that bind CD40 and mesothelin
#142SIRP-α agonist antibody
#143METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS
#144ANTI-GLYCOPROTEIN ANTIBODIES AND USES THEREOF
#145Complex-specific antibodies and antibody fragments and its use
#146BIOMARKER FOR PSYCHIATRIC AND NEUROLOGICAL DISORDERS
#147Recombinant Cell Surface Capture Proteins
#148IMMUNOLOGICAL DETECTION METHOD AND TEST STRIP USED THEREFOR
#149ANTI-CEA ANTIBODIES
#150Pain Treatment
#151Method for decreasing immunogenicity
#152METHOD FOR AFFINITY PURIFICATION
#153ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)
#154BISPECIFIC BINDING PROTEINS
#155Asymmetric multispecific antibodies
#156Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
#157Antibodies that bind activatable antibodies and methods of use thereof
#158Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII)
#159Serum albumin binding proteins containing immunoglobulin single variable domains
#160Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#161Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen
#162RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
#163Enhanced production of immunoglobulins
#164Biotin Derivatives
#165Multiplexed same type-antigenic peptide
#166Immunoglobulin variable domains
#167ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY
#168METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE-RELATED DISEASES OR DISORDERS AND/OR THERAPY MONITORING
#169Dual receptor antagonistic antigen-binding proteins and uses thereof
#170Bispecific antibody fragments for neurological disease proteins and methods of use
#171Human-derived insect-resistant gene and anti-Cry1B toxin idiotype single-chain antibody encoded thereby and application thereof
#172Anti-TNF antibodies, compositions, methods and uses
#173Targeting intracellular target-binding determinants with intracellular antibodies
#174ANTI-CEA ANTIBODIES
#175Antibody conjugates
#176Means and methods for diagnosing and treating multiple sclerosis
#177Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
#178Biomarker for psychiatric and neurological disorders
#179Activatable binding polypeptides and methods of identification and use thereof
#180Single domain antibodies directed against STAT3
#181Single domain antibodies directed against KRAS
#182Single domain antibodies directed against TNF-alpha
#183Methods for treatment comprising an antibody that binds CD223 protein
#184HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS
#185INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE
#186Method for Treating Eclampsia and Preeclampsia
#187METHOD FOR AFFINITY PURIFICATION
#188NON-B-LINEAGE CELLS CAPABLE OF PRODUCING ANTIBODY
#189HUMAN ANTI-KIR ANTIBODIES
#190Antibody-binding protein-drug conjugate and methods of use
#191Antibodies that bind activatable antibodies and methods of use thereof
#192Method for decreasing immunogenicity
#193STABILIZED SINGLE DOMAIN ANTIBODIES
#194TREATMENT DRUG FOR AUTOIMMUNE DISEASES AND ALLERGIC DISEASES
#195Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
#196Targeted Delivery Of Autoantigens To B Cell Populations
#197Anti-drug antibody assay
#198Bispecific antibody fragments for neurological disease proteins and methods of use
#199Fusion protein for suppression of autoantibodies
#200Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
#201JAML specific binding agents, antibodies, and uses related thereto
#202Fibroblast Growth Factor Receptor-Derived Peptides Binding to NCAM
#203Modified proteins and peptides
#204RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
#205Anti-CEA antibodies
#206TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#207Methods for improving drug efficacy including a combination of drug administration and nerve modulation
#208Anti-TNF antibodies, compositions, methods and uses
#209Antibody conjugates
#210Recombinant cell surface capture proteins
#211T Cell Regulation
#212IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES
#213Method for preparing Fc containing polypeptides having improved properties
#214Fibronectin cradle molecules and libraries thereof
#215Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
#216Immunoglobulin cleavage fragments and disease indicators and compositions for detecting and binding such
#217ANTI-IMMUNE COMPLEX ANTIBODIES
#218Assay for detecting free light chains by capillary zone electrophoresis
#219Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain And Mucin Domain 1 (TIM-1) Antigen
#220Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
#221Method for treating cancer with an antibody to CD223 protein
#222Anti B7-H3 antibody
#223Compositions and methods useful for stabilizing protein-containing formulations
#224Anti-TNF antibodies, compositions, methods and uses
#225IMMUNOGLOBULIN CLEAVAGE FRAGMENT VACCINE COMPOSITIONS
#226STABILIZED SINGLE DOMAIN ANTIBODIES
#227Anti-CEA antibodies
#228Activatable binding polypeptides and methods of identification and use thereof
#229Activatable binding polypeptides and methods of identification and use thereof
#230Activatable binding polypeptides and methods of identification and use thereof
#231CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
#232Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
#233Nucleic acids encoding human anti-kir antibodies
#234Antibodies to disulfated heparin disaccharide in the diagnosis of neuropathy
#235Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
#236Fibroblast growth factor receptor-derived peptides binding to NCAM
#237Highly sensitive monoclonal antibody residual detection assay
#238METHOD FOR TREATING IMMUNE DISORDERS
#239HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS
#240METHODS AND PRODUCTS FOR MEASURING FREE IMMUNOGLOBULIN LIGHT CHAIN MOLECULES
#241STABILIZED SINGLE DOMAIN ANTIBODIES
#242Method for decreasing immunogenicity
#243Method for quantification of antigen-specific canine IgE
#244Treatment of thromboangiitis obliterans by removal of autoantibodies
#245Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
#246Method of enhancing homologous recombination of somatic cells and method of constructing specific antibody
#247METHOD OF IMMUNOLOGICAL ANALYSIS FOR DETECTION OF ANTIBODIES AGAINST HUMAN GSTT1 (ANTI-HGSTT1)
#248VESICULAR PHOSPHOLIPID GELS COMPRISING PROTEINACEOUS SUBSTANCES
#249Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
#250Ligand
#251CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES
#252Immunological compositions as cancer biomarkers and/or therapeutics
#253Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
#254Enhancing efficacy of vaccines administered via the respiratory tract
#255Antibodies for determining the prothrombin fragment F2/F1+2 in a homogeneous immunoassay
#256Prevention of aggregation of immunoglobulin light or heavy chains
#257ANTI-DRUG ANTIBODY ASSAY
#258Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
#259ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF
#260Anti-TNF antibodies, compositions, methods and uses
#261Stabilized single domain antibodies
#262Antibody conjugates
#263Immunoglobulin Cleavage Fragments as Disease Indicators and Compositions for Detecting and Binding Such
#264Anti-TNF antibodies, compositions, methods and uses
#265Human anti-KIR antibodies
#266Anti-TNF antibodies, compositions, methods and uses
#267Reagent and kit for early diagnosis of kidney disease
#268Polypeptide microparticles having sustained release characteristics, methods and uses
#269Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
#270Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
#271Method For Affinity Purification
#272Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism
#273Antibodies and methods for making and using them
#274Transgenic ungulates capable of human antibody production
#275Immunogenic recombinant antibody
#276Method of Producing Pan-Specific Antibodies
#277Ligand
#278Treatment of B cell diseases using anti-germline antibody binding agents
#279Natural antibodieactive against HIV virus
#280Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
#281Antibody conjugates
#282T cell regulation
#283Heterodimeric protein binding compositions
#284Method of enhancing homologous recombination of somatic cells and method of constructing specific antibody
#285Modulation of mesenchymal cells via iga-receptors
#286Ligand
#287Vaccine composition for preventing meningococcal disease
#288Ligand
#289Monoclonal antibodies and their use
#290Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
#291Novel high protein tortillas